Biomarin Pharmaceutical Inc (BMRN)
66.60
+0.71
(+1.08%)
USD |
NASDAQ |
Nov 01, 16:00
66.60
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical Net Income (Quarterly): 106.08M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 106.08M |
| June 30, 2024 | 107.17M |
| March 31, 2024 | 88.66M |
| December 31, 2023 | 20.38M |
| September 30, 2023 | 40.38M |
| June 30, 2023 | 56.04M |
| March 31, 2023 | 50.85M |
| December 31, 2022 | -0.249M |
| September 30, 2022 | -6.652M |
| June 30, 2022 | 27.66M |
| March 31, 2022 | 120.80M |
| December 31, 2021 | -57.90M |
| September 30, 2021 | -36.49M |
| June 30, 2021 | 12.94M |
| March 31, 2021 | 17.37M |
| December 31, 2020 | 17.03M |
| September 30, 2020 | 784.80M |
| June 30, 2020 | -29.18M |
| March 31, 2020 | 81.38M |
| December 31, 2019 | 15.02M |
| September 30, 2019 | 55.04M |
| June 30, 2019 | -37.44M |
| March 31, 2019 | -56.47M |
| December 31, 2018 | -3.65M |
| September 30, 2018 | -12.62M |
| Date | Value |
|---|---|
| June 30, 2018 | -16.79M |
| March 31, 2018 | -44.15M |
| December 31, 2017 | -51.39M |
| September 30, 2017 | -12.53M |
| June 30, 2017 | -36.83M |
| March 31, 2017 | -16.29M |
| December 31, 2016 | -90.72M |
| September 30, 2016 | -37.42M |
| June 30, 2016 | -419.01M |
| March 31, 2016 | -83.05M |
| December 31, 2015 | 68.62M |
| September 30, 2015 | -90.93M |
| June 30, 2015 | -81.99M |
| March 31, 2015 | -67.50M |
| December 31, 2014 | -69.80M |
| September 30, 2014 | 7.445M |
| June 30, 2014 | -33.50M |
| March 31, 2014 | -38.12M |
| December 31, 2013 | -61.99M |
| September 30, 2013 | -53.02M |
| June 30, 2013 | -21.53M |
| March 31, 2013 | -39.81M |
| December 31, 2012 | -53.01M |
| September 30, 2012 | -5.357M |
| June 30, 2012 | -32.01M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-57.90M
Minimum
Dec 2021
784.80M
Maximum
Sep 2020
70.80M
Average
24.02M
Median
Net Income (Quarterly) Benchmarks
| Merck & Co Inc | 3.157B |
| Bristol-Myers Squibb Co | 1.211B |
| Alnylam Pharmaceuticals Inc | -111.57M |
| Bioventus Inc | -23.99M |
| Moderna Inc | -1.279B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 745.74M |
| Total Expenses (Quarterly) | 631.87M |
| EPS Diluted (Quarterly) | 0.55 |
| Enterprise Value | 12.36B |
| Gross Profit Margin (Quarterly) | 74.73% |
| Profit Margin (Quarterly) | 14.22% |
| Earnings Yield | 2.51% |
| Operating Earnings Yield | 2.39% |
| Normalized Earnings Yield | 2.444 |